Finally, as recently reported by Sun et al. [81], it is noteworthy that a MoAb directed against the stem cell marker CD133, which frequently is expressed on glioma cells, could be used to deliver a heavily boronated dendrimer to specifically target this cell population, both in vitro and in vivo. The gene discussed is PROM1; the disease is central nervous system cancer.